Show simple item record

dc.rights.licenseopenen_US
dc.contributor.authorUDINA, Marc
dc.contributor.authorMORENO-ESPANA, Jose
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorCAPURON, Lucile
IDREF: 167018736
dc.contributor.authorNAVINES, Ricard
dc.contributor.authorFARRE, Magi
dc.contributor.authorVIETA, Eduard
dc.contributor.authorMARTIN-SANTOS, Rocio
dc.date.accessioned2022-03-16T11:40:31Z
dc.date.available2022-03-16T11:40:31Z
dc.date.issued2014-01-01
dc.identifier.issn1996-3181en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/136487
dc.description.abstractEnCurrent treatments of depression include psychological, pharmacological and physical approaches. Pharmacological interventions to treat depression have previously focused on modifying dysfunctional neurotransmitter systems. Overall, these treatments have demonstrated an ability to manage major depression but otucomes continue to be poor in many patients, especially those with long term illness or with previous multiple relapses. This may be due to the fact that depression is a systemic and neuroprogressive illness involving multiple biological pathways such as immunological factors. There is substantial evidence that cytokine therapies induce depressive symptoms in clinical populations. The model of cytokine-induced depression has provided important information relative to the risk factors and biological pathways involved in the etiology of depressive symptoms and, most importantly, the identification and knowledge of these factors has allowed new treatment targets to be explored. When an exogenous cytokine such as interferon-alpha is administered, proinflammatory cytokines are activated, leading to alterations in neurotransmission and endocrine pathways and producing neurotoxicity. Several new treatments for depression acting through pathways other than amine neurotransmission have emerged in recent years. The regulation of the inflammatory response, the decrease in the activity of the hypothalamic-pituitary-adrenal axis and the prevention of neurotoxicity are potential targets for new drugs. Though these drugs are mostly at the proof-of-concept stage, some of them have already shown promising results for the treatment of depression.
dc.language.isoENen_US
dc.subject.enAnimals
dc.subject.enAntidepressive Agents
dc.subject.enCytokines
dc.subject.enDepression
dc.subject.enHumans
dc.subject.enImmunologic Factors
dc.title.enCytokine-induced depression: current status and novel targets for depression therapy.
dc.title.alternativeCNS Neurol Disord Drug Targetsen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.2174/1871527313666140612121921en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed24923336en_US
bordeaux.journalCNS and Neurological Disorders. Drug Targetsen_US
bordeaux.page1066-74en_US
bordeaux.volume13en_US
bordeaux.hal.laboratoriesNutriNeurO (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINRAEen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=CNS%20and%20Neurological%20Disorders.%20Drug%20Targets&rft.date=2014-01-01&rft.volume=13&rft.issue=6&rft.spage=1066-74&rft.epage=1066-74&rft.eissn=1996-3181&rft.issn=1996-3181&rft.au=UDINA,%20Marc&MORENO-ESPANA,%20Jose&CAPURON,%20Lucile&NAVINES,%20Ricard&FARRE,%20Magi&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record